[go: up one dir, main page]

WO2006056998A3 - Methodes de therapie cellulaire, neurogenese et oligodendrogenese - Google Patents

Methodes de therapie cellulaire, neurogenese et oligodendrogenese Download PDF

Info

Publication number
WO2006056998A3
WO2006056998A3 PCT/IL2005/001270 IL2005001270W WO2006056998A3 WO 2006056998 A3 WO2006056998 A3 WO 2006056998A3 IL 2005001270 W IL2005001270 W IL 2005001270W WO 2006056998 A3 WO2006056998 A3 WO 2006056998A3
Authority
WO
WIPO (PCT)
Prior art keywords
oligodendrogenesis
cell therapy
neurogenesis
methods
neuroprotective agent
Prior art date
Application number
PCT/IL2005/001270
Other languages
English (en)
Other versions
WO2006056998A2 (fr
Inventor
Michal Eisenbach-Schwartz
Oleg Butovsky
Yaniv Ziv
Jonathan Kipnis
Noga Ron
Original Assignee
Yeda Res & Dev
Michal Eisenbach-Schwartz
Oleg Butovsky
Yaniv Ziv
Jonathan Kipnis
Noga Ron
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev, Michal Eisenbach-Schwartz, Oleg Butovsky, Yaniv Ziv, Jonathan Kipnis, Noga Ron filed Critical Yeda Res & Dev
Priority to US11/720,417 priority Critical patent/US20090010873A1/en
Publication of WO2006056998A2 publication Critical patent/WO2006056998A2/fr
Publication of WO2006056998A3 publication Critical patent/WO2006056998A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0622—Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2304—Interleukin-4 (IL-4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/08—Coculture with; Conditioned medium produced by cells of the nervous system
    • C12N2502/086—Coculture with; Conditioned medium produced by cells of the nervous system glial cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne une méthode permettant d'induire et d'améliorer la neurogenèse et/ou l'oligodendrogenèse à partir de cellules souches endogènes ainsi que de cellules souches administrées de façon exogène. Cette méthode consiste à administrer à un individu le nécessitant un agent neuroprotecteur, tel qu'un antigène spécifique du système nerveux, un peptide dérivé associé, des lymphocytes T activés, poly-YE, une microglie activée par IFN-? et/ou IL-4 et des combinaisons associées. Cette méthode comprend une thérapie de cellules souches combinée à l'agent neuroprotecteur.
PCT/IL2005/001270 2004-11-29 2005-11-29 Methodes de therapie cellulaire, neurogenese et oligodendrogenese WO2006056998A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/720,417 US20090010873A1 (en) 2004-11-29 2005-11-29 Methods of Cell Therapy, Neurogenesis and Oligodendrogenesis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63116304P 2004-11-29 2004-11-29
US60/631,163 2004-11-29

Publications (2)

Publication Number Publication Date
WO2006056998A2 WO2006056998A2 (fr) 2006-06-01
WO2006056998A3 true WO2006056998A3 (fr) 2009-04-30

Family

ID=36498358

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2005/001270 WO2006056998A2 (fr) 2004-11-29 2005-11-29 Methodes de therapie cellulaire, neurogenese et oligodendrogenese

Country Status (2)

Country Link
US (1) US20090010873A1 (fr)
WO (1) WO2006056998A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8241903B2 (en) * 2006-06-22 2012-08-14 Yeda Research And Development Co., Ltd. Catecholamine receptor modulation
WO2008001379A2 (fr) * 2006-06-28 2008-01-03 Yeda Research And Development Co. Ltd Cellules myéloïdes activées servant à favoriser la réparation des tissus et à détecter un tissu endommagé
US20100299770A1 (en) * 2007-06-12 2010-11-25 Selkirk Stephen M Targeted cell death
WO2009081395A1 (fr) * 2007-12-21 2009-07-02 Ben Gurion University Of The Negev Research And Development Authority Procédé de traitement de maladies neurodégénératives
EP2280716A1 (fr) * 2008-04-15 2011-02-09 Yeda Research And Development Company Ltd. Agents et procédés pour le traitement de troubles de l'anxiété
JP5657556B2 (ja) * 2008-11-11 2015-01-21 ターガセプト，インコーポレイテッド α７選択的リガンドを用いる治療
EP2473031A4 (fr) * 2009-09-02 2013-12-04 Univ Chicago Procédés et systèmes d' ablation pouvant être induite de cellules neuronales
WO2012066495A2 (fr) * 2010-11-17 2012-05-24 Ben Gurion University Of The Negev Research And Development Authority Thérapie à base de cellules t pour les maladies neurodégénératives
EP3320914B1 (fr) * 2012-09-10 2020-12-30 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Adjuvant t-helper 1 pour le traitement de la sclérose latérale amyotrophique
US10854826B2 (en) 2014-10-08 2020-12-01 Universal Display Corporation Organic electroluminescent compounds, compositions and devices
US11389509B1 (en) * 2017-07-12 2022-07-19 University Of Virginia Patent Foundation Methods for treatment of social dysfunction neurological disorders and seizures

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7114165B2 (en) * 2002-11-29 2006-09-26 Lite-On It Corporation Clamping device for an optical disk player

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270191A (en) * 1988-04-12 1993-12-14 Massachusetts Institute Of Technology Method for manipulation of the cell types of eukaryotes
WO1996028470A2 (fr) * 1995-03-09 1996-09-19 Neurocrine Biosciences, Inc. Analogues peptidiques de proteine de base de myeline utile dans le traitement de la sclerose en plaques
US6653134B2 (en) * 1995-03-28 2003-11-25 Cp Hahnemann University Isolated stromal cells for use in the treatment of diseases of the central nervous system
US6267955B1 (en) * 1995-09-15 2001-07-31 Yeda Research And Development Co. Ltd. Mononuclear phagocytes and their use to promote axonal regeneration
US5800812A (en) * 1995-09-15 1998-09-01 Yeda Research And Development Co. Ltd. Methods of use of mononuclear phagocytes to promote axonal regeneration
US5753506A (en) * 1996-05-23 1998-05-19 Cns Stem Cell Technology, Inc. Isolation propagation and directed differentiation of stem cells from embryonic and adult central nervous system of mammals
US6126939A (en) * 1996-09-03 2000-10-03 Yeda Research And Development Co. Ltd. Anti-inflammatory dipeptide and pharmaceutical composition thereof
US5968829A (en) * 1997-09-05 1999-10-19 Cytotherapeutics, Inc. Human CNS neural stem cells
US5958767A (en) * 1998-08-14 1999-09-28 The Children's Medical Center Corp. Engraftable human neural stem cells
US7119165B2 (en) * 2000-01-12 2006-10-10 Yale University Nogo receptor-mediated blockade of axonal growth
US6838711B1 (en) * 2003-09-08 2005-01-04 National Semiconductor Corporation Power MOS arrays with non-uniform polygate length

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7114165B2 (en) * 2002-11-29 2006-09-26 Lite-On It Corporation Clamping device for an optical disk player

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HARDIN ET AL.: "Activation of dopamine cell fireing by repeated I-dopa administration to dopamine-depleted rats: its poteintial role in mediating the thereapeutic response to 1-dopa treatment.", THE JORNAL OF NEUROSCIENC., vol. 15, September 1995 (1995-09-01), pages 6157 - 6166 *
KIM, SU.: "Human stem cells genetically modified for brain repair in neurological disorders.", NEUROPATHOLOGY., vol. 24, pages 159 - 171 *
WONG ET AL.: "Interferon gamma promotes neuronal differentiation and neurite outgrowth of murine adult neural stem cells.", EXPERIMENTAL NEUROLOGY., vol. 187, May 2004 (2004-05-01), pages 171 - 177 *

Also Published As

Publication number Publication date
WO2006056998A2 (fr) 2006-06-01
US20090010873A1 (en) 2009-01-08

Similar Documents

Publication Publication Date Title
WO2007149548A3 (fr) Traitement d'un dysfonctionnement érectile par une thérapie à base de cellules souches
WO2006056998A3 (fr) Methodes de therapie cellulaire, neurogenese et oligodendrogenese
WO2007047978A3 (fr) Modulation de la neurogenese par inhibition de la pde
WO2006057003A3 (fr) Induction de neurogenese et therapie par cellules souches en combinaison avec le copolymere 1
WO2005092380A3 (fr) Utilisations d'anticorps anti-ctla-4
WO2008067389A3 (fr) Modulation de maladies neurodégénératives
WO2007134077A3 (fr) Neurogenèse induite par le récepteur 5ht
WO2008039874A3 (fr) Vaccins comprenant des antigènes de cellules souches cancéreuses et procédés
WO2005062881A3 (fr) Therapie genique faisant intervenir des vecteurs de transposon
WO2005067660A3 (fr) Systemes et methodes de prothese dimensionnee et configuree pour recevoir et retenir des fixations
WO2001091728A3 (fr) Formulations pour nanoemulsions
WO2003059276A3 (fr) Nouvelles cellules souches multipotentes d'origine mammalienne, methodes de preparation et methodes d'administration desdites cellules
WO2006066244A3 (fr) Procede d'extension de la duree de vie et de retardement de l'apparition de maladies associees au vieillissement
WO2004089307A3 (fr) Derives de spiropiperidine acyles utilises comme agonistes vis-a-vis du recepteur de melanocortine-4
WO2008033403A3 (fr) Agents et méthodes visant à induire une réponse immune antitumorale
WO2005009950A3 (fr) Derives de piperidine utilises en tant qu'agonistes du recepteur de la melanocortine 4
WO2007081896A3 (fr) Compositions pharmaceutiques et méthodes de vaccination contre les candidoses disséminées et d'autres agents infectieux
WO2005120557A3 (fr) Inhibition du recepteur proteique stimulant les macrophages (ron)
WO2006029010A3 (fr) Methodes d'activation de cellules nkt
WO2005094554A3 (fr) Agents, methodes et traitements therapeutiques
WO2006107601A3 (fr) Transplantation de parathyroides et du thymus chez des sujets atteints par le syndrome de digeorge
WO2003102162A3 (fr) Nouvelles cellules dendritiques tolerogeniques et utilisations therapeutiques de celles-ci
NO20060637L (no) Autologe selv-toleranse induserende celler av monocytisk opprinnelse og deres anvendelse i farmasoytiske preparater
WO2006020277A3 (fr) Derives de piperidine acyles utilises en tant qu'agonistes du recepteur de la melanocortine 4
WO2006020949A3 (fr) Therapie genique combinee destinee au traitement de gliomes macroscopiques

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 11720417

Country of ref document: US

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 05810929

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 05810929

Country of ref document: EP

Kind code of ref document: A2